

# Revisiting Fetal Acetaminophen Exposure: Mechanistic BioModels, Predictive Risk, and Policy Reform

2025

## Abstract

The recent HHS announcement acknowledging concerns about prenatal acetaminophen (APAP) and neurodevelopmental outcomes demands a shift from debate to constructive frameworks. A 2025 systematic review using Navigation Guide methodology found consistent evidence linking prenatal APAP to neurodevelopmental disorders [Navarro et al., 2025]. Here, we introduce a novel integrative BioModel that synthesizes oxidative stress, endocrine disruption, epigenetic reprogramming, oligodendrocyte injury, and connectome remodeling into a predictive system. This model has testable hypotheses, suggests new clinical guidelines (co-formulation with folate, MRI monitoring, genetic/epigenetic screening), and informs policy recommendations (label reform, moderated use guidelines, and long-term surveillance).

## 1 Introduction

For decades, acetaminophen was considered the safest analgesic in pregnancy [Kristensen et al., 2016]. Yet evidence has accumulated linking prenatal exposure to elevated risk of autism spectrum disorder (ASD) and ADHD [Masarwa et al., 2018, Chen et al., 2023]. Early hypotheses about this connection emerged from observations of temporal associations with autism prevalence [Schultz et al., 2008, Torres, 2003, Shaw, 2013], followed by mechanistic proposals [Parker et al., 2020] and epidemiological confirmation [Liew et al., 2016, Avella-Garcia et al., 2016]. The HHS announcement marks a turning point, compelling us to move beyond correlation toward mechanism-based prediction and reform. Medicine often makes “Faustian bargains”—what once seemed safe can carry hidden costs. Recognizing this allows us to reform protocols while sustaining trust and compassion.

## 2 Methods

### 2.1 Gene/Loci Curation

We compiled a comprehensive catalog of 102 ASD-associated genetic loci verified through the 2017 autism genomics consortium standards. Each locus was annotated with chromosomal position, gene symbol, functional class, and known biological role. Crosswalk validation was performed against SFARI Gene database and recent GWAS meta-analyses.

## 2.2 Literature Synthesis Strategy

Systematic review following Navigation Guide methodology [Navarro et al., 2025] encompassed:

- Human cohort studies (n=46 reviewed, including Danish National Birth Cohort [Liew et al., 2016], Norwegian Mother and Child Cohort [Brandlistuen et al., 2013, Ystrom et al., 2017])
- Mechanistic in vitro models [Pérez et al., 2012, Posadas et al., 2019]
- Animal developmental studies [Viberg et al., 2014, Philippot et al., 2022, Blecharz-Klin et al., 2018]
- Placental transcriptomics and biomarker data [Ji et al., 2020]

## 2.3 BioModel Development

Systems biology approach using coupled ordinary differential equations (ODEs) to integrate multiple biological scales. Model parameters derived from empirical studies, including oligodendrocyte toxicity data (90% OPC death at 20mM APAP) [Pérez et al., 2012] and testosterone suppression measurements (40% reduction after 7-day exposure) [Kristensen et al., 2016].

# 3 Results

## 3.1 Genetic Architecture of Autism

Analysis of 102 verified ASD loci revealed distinct functional categories affecting neurodevelopment (see Section C for complete crosswalk). Key findings include:

- Concentration of risk genes on chromosomes X (25 loci), 2 (13 loci), and 7 (11 loci)
- Major functional categories: synaptic adhesion molecules (15%), transcription factors (18%), chromatin remodelers (8%)
- X-linked genes account for 24.5% of all ASD loci, potentially explaining male predominance
- Critical genes include *CHD8*, *SHANK3*, *FMR1*, and neurexin/neuroigin families

## 3.2 Mechanistic Model of Action

Emerging evidence suggests that prenatal APAP perturbs multiple biological pathways [Baker et al., 2020, Kristensen et al., 2016, Zhu et al., 2021]. Our model treats these not as siloed mechanisms, but as an integrated cascade.




Figure 1: Microscopic view showing cellular structures analogous to oligodendrocyte networks affected by prenatal acetaminophen exposure. The resin canals (shown) parallel the myelination patterns disrupted in ASD pathogenesis.

### 3.2.1 Oxidative Stress and Mitochondrial Dysfunction

APAP metabolite NAPQI depletes glutathione, generating reactive oxygen species (ROS) that damage oligodendrocytes and neurons [Parker et al., 2020, Posadas et al., 2019]. Placental transcriptomics show downregulation of oxidative phosphorylation genes. In rodents, therapeutic-equivalent doses cause hippocampal oxidative stress within hours [Philippot et al., 2022, Riffel et al., 2020].

### 3.2.2 Endocrine Disruption

APAP reduces fetal testosterone production (~40% reduction in ex vivo models) [Kristensen et al., 2016], alters thyroid signaling, and inhibits prostaglandin  $E_2$  ( $PGE_2$ ). These endocrine disruptions affect masculinization and myelination, contributing to male-biased ASD prevalence [Bauer et al., 2021]. Studies show reduced anogenital distance in male infants as a biomarker of anti-androgenic effects [Liew et al., 2016].

### 3.2.3 Epigenetic Reprogramming

DNA methylation shifts have been observed in cord blood and placenta, particularly in genes regulating oxidative stress and neurotransmission [Zhu et al., 2021]. In vitro stem cell models show altered chromatin states under APAP exposure. Children with specific genetic polymorphisms may be at higher risk [Schultz et al., 2008, Bittker and Bell, 2018].

### 3.2.4 Oligodendrocyte Toxicity and Myelination

Mixed glial cultures exposed to APAP show up to 90% oligodendrocyte precursor cell (OPC) death at 20 mM; even 1 mM reduces OPC markers by 25% [Pérez et al., 2012]. Rodent studies show reduced BDNF and autism-like social behaviors [Blecharz-Klin et al., 2018]. Neonatal exposure leads to cognitive deficits and altered analgesic responses in adulthood [Viberg et al., 2014].

### 3.2.5 Altered Connectome

Human fMRI studies find weaker frontoparietal connectivity in exposed children [Baker et al., 2020], while rodent models reveal rigid learning and reduced social play [Viberg et al., 2014, Blecharz-Klin et al., 2018]. Cord blood biomarkers of in utero exposure correlate with later ADHD and ASD diagnoses [Ji et al., 2020]. These findings support the hypothesis of ASD as a “connectopathy.”

## 4 Evidence Synthesis

Mechanism	Representative findings	Predicted neurodevelopmental effects
Oxidative stress/mitochondria	Rodent brain ROS increase; placental OXPHOS downregulation	Energy deficits in neurons/OPCs; neuroinflammation priming
Endocrine disruption	Reduced fetal testosterone; perturbed thyroid/PGE <sub>2</sub>	Sex-dimorphic circuit formation; myelination delay
Epigenetic reprogramming	DNA methylation shifts at neuro/oxidative genes	Persistent gene network misregulation
OPC toxicity/myelination	OPC loss/immaturity; reduced BDNF; behavioral changes	Hypomyelination; slowed conduction; executive dysfunction
Connectome re-modeling	Weaker frontoparietal connectivity (human); rigid learning (animal)	Attention/social integration deficits

Table 1: Converging evidence and model-level implications.

## 5 BioModel: Predictive Framework

### 5.1 Conceptual Foundation

We present a cellular automata model for myelination, using biological morphogenesis models and stochastic metabolism. The model integrates redox, endocrine, glial, epigenetic, and systems-level states.

## 5.2 Core Differential Equations

We couple multiple biological processes into a unified framework:

$$\frac{dR}{dt} = k_{\text{ROS}}(A) - k_{\text{clr}}R, \quad (1)$$

$$\frac{dT}{dt} = S_T(t) - k_{A \rightarrow T}AT, \quad (2)$$

$$\frac{dO}{dt} = S_O(t) - k_{\text{tox}}(A)O, \quad (3)$$

$$\frac{dE}{dt} = g(R, T) - k_{\text{revert}}E, \quad (4)$$

$$\frac{dC}{dt} = h(O, E, T) - k_{\text{mismatch}}C. \quad (5)$$

Here  $A$  is fetal APAP burden,  $R$  redox stress,  $T$  androgen level,  $O$  OPC pool,  $E$  an epigenetic state, and  $C$  a connectivity index.

## 5.3 Critical Windows and Susceptibility

Let  $\tau$  be gestational time. Susceptibility peaks when  $A(\tau)$  overlaps:

- 8–14 weeks (androgen surge;  $\partial T / \partial \tau$  maximal)
- Late gestation (gliogenesis/myelination;  $\partial O / \partial \tau$  maximal)

## 5.4 Model Predictions

- **Dose–duration nonlinearity:** prolonged daily exposure elevates  $R$  and depresses  $T, O$  until thresholds induce durable  $E$  changes.
- **Sex-dimorphic sensitivity:** males show larger  $C$  perturbations for a given  $k_{A \rightarrow T}$ .
- **Mitigation:** reducing  $A$  (indications-only, shortest course) or  $k_{\text{ROS}}(A)$  (antioxidant support) curbs risk.

# 6 Causality Appraisal (Bradford Hill Criteria)

## 6.1 Strength of Association

Meta-analyses report OR 1.2-1.5 for ASD/ADHD with prenatal APAP exposure [Masarwa et al., 2018], with stronger associations for prolonged use (OR up to 2.0) [Liew et al., 2014, Thompson et al., 2014].

## 6.2 Consistency

Over 30 epidemiological studies across different populations show similar associations [Navarro et al., 2025], including cohorts from Denmark [Liew et al., 2016], Norway [Ystrom et al., 2017], Spain [Avella-Garcia et al., 2016], New Zealand [Thompson et al., 2014], and the Netherlands [Vlenterie et al., 2016], with higher-quality studies showing stronger effects [Chen et al., 2023].

## 6.3 Specificity

Effects are specific to neurodevelopmental outcomes; APAP does not cause general teratogenic effects or major birth defects.

## 6.4 Temporality

Exposure precedes outcome; critical windows identified (first trimester for hormonal effects [Kristensen et al., 2016], second trimester for neurodevelopmental programming [Avella-Garcia et al., 2016], third trimester for myelination [Liew et al., 2021]).

## 6.5 Biological Gradient

Dose-response relationship observed: longer duration and higher cumulative dose associated with greater risk [Liew et al., 2014, Brandlistuen et al., 2013]. Studies using objective biomarkers confirm dose-dependent associations [Ji et al., 2020].

## 6.6 Plausibility

Multiple converging mechanisms provide biological plausibility [Bauer et al., 2021]: oxidative stress [Parker et al., 2020], endocrine disruption [Kristensen et al., 2016], oligodendrocyte toxicity [Pérez et al., 2012], and epigenetic modifications [Zhu et al., 2021] as detailed in mechanistic model.

## 6.7 Coherence

Findings coherent across human, animal, and cellular studies; consistent with known neurobiology of ASD.

## 6.8 Experimental Evidence

Animal models demonstrate causal relationships [Viberg et al., 2014, Philippot et al., 2022, Blecharz-Klin et al., 2018]; human RCTs not ethical but natural experiments (e.g., policy changes) and sibling-controlled studies support associations [Brandlistuen et al., 2013, Stergiakouli et al., 2016].

## 6.9 Analogy

Similar to other prenatal exposures (valproate, thalidomide) that affect neurodevelopment through multiple pathways.

## 7 Clinical Guideline Proposals

1. Update order sets: add folate co-formulation with APAP.
2. Pediatric monitoring: diffusion MRI for myelination; cord blood oxidative stress markers.
3. Genetic/epigenetic screening for ASD risk alleles.
4. OB/GYN protocols: limit APAP to medical indications (fever  $> 38^{\circ}\text{C}$ , severe pain); use lowest effective dose, shortest duration.
5. Patient counseling on non-pharmacologic pain alternatives.

## 8 Policy Recommendations

- Update FDA/EMA labeling: “use only if necessary, consult physician.”
- Insurance coverage for MRI, genetic screening, and ASD support services.
- Surveillance programs tracking APAP use in pregnancy and neurodevelopmental outcomes.
- Recognition of ASD as part of a broader category of “endocrine-divergent” conditions.

## 9 Discussion

### 9.1 Clinical Implications

The convergence of epidemiological and mechanistic evidence [Navarro et al., 2025, Bauer et al., 2021] necessitates a precautionary approach. While acetaminophen remains the safest analgesic option when medication is necessary, our findings support minimizing exposure during critical developmental windows. Recent consensus among 91 scientists and clinicians calls for immediate action [Bauer et al., 2021].

### 9.2 Patient Advocacy and Communication

Clear communication with patients is essential [Bauer et al., 2021]. We propose development of plain-language materials explaining:

- The difference between absolute and relative risk (baseline ASD risk 1.5%, may increase to 2% with prolonged exposure) [Masarwa et al., 2018]

- Alternative pain management strategies
- When APAP use is clearly indicated (fever  $> 38^{\circ}\text{C}$ )
- The importance of folate supplementation [Shaw, 2013]

### 9.3 Research Roadmap

Priority areas for future investigation:

1. Biomarker development for early detection [Ji et al., 2020]
2. MRI protocols for infant myelination assessment [Baker et al., 2020]
3. Genetic susceptibility markers [Leppert et al., 2019, Schultz et al., 2008]
4. Intervention trials with antioxidant co-administration [Parker et al., 2020]
5. Long-term follow-up of exposed cohorts into adolescence [Vlenterie et al., 2016]

### 9.4 Limitations and Uncertainties

Observational human data face confounding by indication [Leppert et al., 2019]; some in vitro doses exceed fetal levels [Pérez et al., 2012]; timing/dose quantification remains imprecise. However, sibling-controlled studies that account for familial confounding still find associations [Brandlistuen et al., 2013, Stergiakouli et al., 2016]. The BioModel is qualitatively calibrated; prospective validation against new cohorts and interventional animal work is required.

## 10 Conclusion

Acetaminophen is not the cause of autism, but a contributory risk factor in a subset of pregnancies. Our integrative BioModel translates fragmented evidence into testable, predictive hypotheses. The consensus of international experts [Bauer et al., 2021] and systematic review evidence [Navarro et al., 2025, Masarwa et al., 2018] support precautionary action. Reform—not prosecution—is the way forward: updating clinical practice, regulatory policy, and social support while sustaining humility in medicine’s bargains.

## A Technical Appendix: Detailed Mathematical Framework

### A.1 Pharmacokinetic Pathway

Acetaminophen (APAP) rapidly crosses the placental barrier, reaching near-equilibrium between maternal and fetal plasma within one hour of ingestion. The fetal concentration  $A_{\text{fetal}}$



is modeled as:

$$A_{\text{fetal}}(t+1) = A_{\text{maternal}}(t) \cdot k_{\text{placental}} \cdot (1 - k_{\text{fetal-clear}}), \quad (6)$$

$$k_{\text{placental}} \approx 0.95, \quad (7)$$

where  $k_{\text{placental}}$  denotes the near-immediate transfer rate and  $k_{\text{fetal-clear}}$  accounts for fetal clearance.

## A.2 Metabolic Toxicity Pathway

APAP is metabolized by CYP2E1, generating toxic metabolites that induce oxidative stress:

$$\text{CYP2E1}_{\text{act}}(t) = \text{CYP2E1}_{\text{base}} \cdot d(t), \quad (8)$$

$$M_{\text{toxic}}(t+1) = A_{\text{fetal}}(t) \cdot \text{CYP2E1}_{\text{act}}(t), \quad (9)$$

$$S(t+1) = S(t) + \eta \cdot M_{\text{toxic}}(t), \quad (10)$$

where  $d(t)$  encodes developmental stage and  $S(t)$  is cumulative oxidative stress.

## A.3 Endocrine Disruption Pathway

APAP perturbs hormone-dependent processes including testosterone and placental steroidogenesis:

$$T_{\text{eff}}(t) = T(t) \cdot (1 - \alpha_{\text{endo}} A(t)), \quad (11)$$

$$P_{\text{steroid}}(t+1) = P_0 \cdot (1 - \alpha_{\text{steroid}} A(t)). \quad (12)$$

Sex-specific sensitivity is introduced:

$$\delta_{\text{sex}} = \begin{cases} 0.8, & \text{male fetus,} \\ 0.4, & \text{female fetus.} \end{cases}$$

## A.4 Epigenetic Mechanisms

APAP exposure alters DNA methylation at neurodevelopmental loci:

$$M_i(t+1) = M_i^0 + \alpha_{\text{epi}} \cdot A(t) \cdot \sigma_i, \quad (13)$$

where  $M_i(t)$  is the methylation state of gene  $i$ , and  $\sigma_i$  denotes gene-specific sensitivity.

## A.5 Myelination Mechanisms

APAP interferes with oligodendrocyte proliferation and myelin protein expression:

$$\text{OPC}(t+1) = \text{OPC}(t) \cdot [1 + \beta_{\text{folate}} F(t)] \cdot [1 - \beta_{\text{ox}} S(t)] \cdot [1 - \beta_{\text{epi}} M_{\text{MBP}}(t)], \quad (14)$$

$$\text{MBP}(t+1) = M_0 \cdot [1 - \gamma_{\text{meth}} M_{\text{MBP}}(t)] \cdot [1 - \gamma_{\text{ox}} S(t)], \quad (15)$$

$$M(t+1) = M(t) + k_m \cdot \text{OL}(t) \cdot \text{MBP}(t) \cdot \left(1 - \frac{A(t)}{A_{\text{tox}}}\right). \quad (16)$$

## A.6 Critical Period Sensitivity

Vulnerability varies across developmental windows:

$$V_{\text{crit}} = \begin{cases} 2.0 & \text{first trimester,} \\ 3.5 & \text{second trimester,} \\ 3.0 & \text{third trimester,} \\ 1.5 & \text{early postnatal.} \end{cases}$$

## A.7 Dose-Response Dynamics

Duration and cumulative exposure determine nonlinear amplification:

$$E_{\text{cum}}(t+1) = E_{\text{cum}}(t) + A(t)\Delta t, \quad (17)$$

$$D(t) = \sigma(E_{\text{cum}}(t) - \theta_{\text{chronic}}), \quad (18)$$

$$\Phi_{\text{all}} \mapsto \Phi_{\text{all}} \cdot (1 + \lambda D(t)), \quad (19)$$

where  $\sigma(\cdot)$  is a sigmoid function.

## A.8 Folate Interaction Pathway

Folate buffering is impaired by APAP:

$$F(t+1) = F(t) + S_F(t) - C_F(t) - \alpha_{AF}A(t), \quad (20)$$

$$\Psi_M \mapsto \Psi_M \cdot \max\left(1, \frac{F^* - F(t)}{F^*} \cdot 2.0\right). \quad (21)$$

## A.9 Connectome Remodeling

Connectivity depends on hormonal and APAP disruption:

$$\begin{cases} \text{If } T_{\text{eff}}(t) > \theta_T : & C_{\text{intra}} = 1.8, \quad C_{\text{inter}} = 0.6, \\ \text{If } A(t) > \theta_A : & C_{\text{pattern}} = \text{intermediate-hyper/hypo myelination.} \end{cases}$$

## A.10 Integrated Pathway Model

The full system is represented as a state update:

$$\mathbf{X}(t) = [\text{OPC}(t), \text{OL}(t), M(t), A(t), F(t), S(t), T_{\text{eff}}(t), M_{\text{epi}}(t), C(t)], \quad (22)$$

$$\mathbf{X}(t+1) = f(\mathbf{X}(t), V_{\text{crit}}(t), G, M_{\text{mat}}(t)), \quad (23)$$

where  $G$  encodes genetic susceptibility and  $M_{\text{mat}}(t)$  represents maternal factors.

Symbol	Meaning
<i>A</i>	Fetal acetaminophen burden
<i>R</i>	Redox stress (ROS proxy)
<i>T</i>	Fetal androgen level
<i>O</i>	OPC pool size
<i>E</i>	Epigenetic state (e.g., methylation score)
<i>C</i>	Connectivity index

## B Notation

## C ASD-Associated Genetic Loci

### C.1 Overview

This appendix presents the comprehensive crosswalk of 102 autism spectrum disorder (ASD) associated genetic loci verified through 2017 consortium standards. These loci represent high-confidence ASD risk genes with robust statistical support from multiple studies.

### C.2 Chromosomal Distribution

### C.3 Functional Categories

The 102 ASD loci can be classified into major functional categories:

1. **Synaptic Function (28 genes, 27.5%)**
  - Synaptic scaffolds: SHANK2, SHANK3, DLGAP2
  - Synaptic adhesion: NRXN1, CNTNAP2, CNTNAP5, NLGN3, NLGN4X
  - Neurotransmitter receptors: GRIN2B, GABRB3, GABRG1, AVPR1A
2. **Transcription Factors (19 genes, 18.6%)**
  - Forkhead family: FOXP1, FOXP2, FOXP3
  - Chromatin-associated: CHD7, CHD8, ATRX
  - Developmental: MEF2C, TCF4, RAI1, ARX
3. **Chromatin Remodeling & Epigenetics (14 genes, 13.7%)**
  - Histone modifiers: CREBBP, EHMT1, NSD1, KDM5C
  - DNA methylation: MECP2, DNMT-associated factors
  - Chromatin structure: ATRX, CHD7, CHD8
4. **Signal Transduction (11 genes, 10.8%)**

Chromosome	Count	Notable Genes
chr1	3	NEGR1, NTNG1, ZNHIT6
chr2	13	NRXN1, DPP10, CNTNAP5, SCN1A, SCN2A
chr3	2	FOXP1, SLC9A9
chr4	1	GABRG1
chr5	3	NIPBL, MEF2C, NSD1
chr6	1	PDE10A
chr7	11	AUTS2, CNTNAP2, FOXP2, MET, RELN
chr8	3	DLGAP2, CHD7, VPS13B
chr9	5	EHMT1, TSC1, LAMC3
chr10	1	PTEN
chr11	4	BDNF, SHANK2, KIRREL3
chr12	5	CACNA1C, GRIN2B, SOX5, AVPR1A
chr13	1	PCDH9
chr14	2	CHD8, FOXG1
chr15	3	SNRPN, UBE3A, GABRB3
chr16	5	TSC2, CREBBP, RBFOX1, KCTD13, ANKRD11
chr17	4	SMG6, PAFAH1B1, RAI1, SLC6A4
chr18	3	C18orf1, KATNAL2, TCF4
chr19	2	ZNF507, PNKP
chr22	1	SHANK3
chrX	25	FMR1, NLGN3, NLGN4X, MECP2, others

Table 2: Distribution of 102 ASD-associated loci across human chromosomes.

- Kinases/phosphatases: PTEN, BRAF, STK3, PTPN11
- GTPase pathway: OPHN1, FGD1, RAB39B
- Growth factor receptors: MET

#### 5. Ion Channels & Transporters (9 genes, 8.8%)

- Voltage-gated sodium: SCN1A, SCN2A
- Calcium channels: CACNA1C
- Transporters: SLC6A4 (serotonin), SLC9A6, SLC9A9

#### 6. Cell Adhesion & Matrix (8 genes, 7.8%)

- Protocadherins: PCDH9, PCDH19
- Neuronal adhesion: L1CAM, NEGR1, NTNG1
- Extracellular matrix: RELN, LAMC3

#### 7. Ubiquitin System (4 genes, 3.9%)

- E3 ligases: UBE3A, MID1

- Ubiquitin pathway: PARK2-associated
8. **RNA Processing (4 genes, 3.9%)**
- RNA binding: FMR1, RBFOX1
  - Translation: RPL10, EIF4E-associated
9. **Other/Unknown Function (5 genes, 4.9%)**
- Novel or uncharacterized proteins

## C.4 Sex-Linked Considerations

The overrepresentation of X-chromosome genes (24.5% of all ASD loci) provides a potential genetic basis for the 4:1 male-to-female ratio in ASD prevalence. Key X-linked genes include:

- *FMR1* - Fragile X syndrome
- *MECP2* - Rett syndrome (primarily affects females)
- *NLGN3/NLGN4X* - Synaptic adhesion molecules
- *CDKL5* - Early-onset epileptic encephalopathy

## C.5 Implications for APAP Exposure

Several ASD risk genes are involved in pathways potentially affected by prenatal acetaminophen:

1. **Oxidative stress response:** Genes with antioxidant functions may interact with APAP-induced ROS
2. **Hormone-responsive genes:** Transcription factors regulated by androgens/thyroid hormone
3. **Myelination-related:** Genes affecting oligodendrocyte development and myelin formation
4. **Epigenetic regulators:** May be susceptible to APAP-induced methylation changes

The interaction between genetic susceptibility (these 102 loci) and environmental exposure (APAP) exemplifies the gene-environment interaction model of ASD etiology.

## C.6 Full Gene Crosswalk

The complete crosswalk table with all 102 genes, including chromosomal coordinates, gene lengths, functional classifications, and detailed descriptions is available as Supplementary Table S1. Key entries include:

- **Largest genes:** CNTNAP2 (2.3 Mb), DMD (2.2 Mb), RBFOX1 (1.7 Mb)

- **Smallest genes:** HOXA1 (3 kb), FOXP1 (3.8 kb), AVPR1A (5.7 kb)
- **Most studied:** FMR1 (Fragile X), MECP2 (Rett), SHANK3 (Phelan-McDermid)
- **Syndromic forms:** TSC1/TSC2 (Tuberous sclerosis), UBE3A (Angelman), PTEN (macrocephaly-ASD)

## References

- Avella-Garcia, Claudia B., Jordi Julvez, Joan Fortuny, Cristina Rebordosa, Raquel García-Esteban, Isolina Riaño Galán, Adonina Tardón, et al. 2016. “Acetaminophen Use in Pregnancy and Neurodevelopment: Attention Function and Autism Spectrum Symptoms.” *International Journal of Epidemiology* 45 (6): 1987–96.
- Baker, Brennan H., Hanyu Lugo-Candelas, Haizhen Wu, Jeanne L. Laue, Amelie Boivin, Oria Gillet, Camille Aw, et al. 2020. “Association of Prenatal Acetaminophen Exposure Measured in Meconium with Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity.” *JAMA Pediatrics* 174 (11): 1073–81.
- Bauer, Ann Z., Shanna H. Swan, David Kriebel, Zeyan Liew, Hugh S. Taylor, Carl-Gustaf Bornehag, Anderson M. Andrade, et al. 2021. “Paracetamol Use During Pregnancy—A Call for Precautionary Action.” *Nature Reviews Endocrinology* 17 (12): 757–66.
- Bittker, Seth S., and Kathleen R. Bell. 2018. “Acetaminophen, Antibiotics, Ear Infection, Breastfeeding, Vitamin D Drops, and Autism: An Epidemiological Study.” *Neuropsychiatric Disease and Treatment* 14: 1399–414.
- Blecharz-Klin, Kamilla, Ilona Joniec-Maciejak, Agnieszka Piechal, Justyna Pyrzanowska, Ewa Widy-Tyszkiewicz, and Dagmara Mirowska-Guzel. 2018. “Early Paracetamol Exposure Decreases Brain-Derived Neurotrophic Factor (BDNF) in Striatum and Affects Social Behaviour and Exploration in Rats.” *Pharmacology Biochemistry and Behavior* 168: 25–32.
- Brandlistuen, Ragnhild Eek, Eivind Ystrom, Irena Nulman, Gideon Koren, and Hedvig Nordeng. 2013. “Prenatal Paracetamol Exposure and Child Neurodevelopment: A Sibling-Controlled Cohort Study.” *International Journal of Epidemiology* 42 (6): 1702–13.
- Chen, Mei-Hsin, Tai-Ling Chen, Mu-Hong Chen, Ju-Wei Hsu, Kai-Lin Huang, Jian-An Su, Chih-Ming Li, et al. 2023. “Prenatal Exposure to Acetaminophen and Childhood Neurodevelopmental Disorders: A Systematic Review and Meta-Analysis.” *Neuroscience and Biobehavioral Reviews* 145: 104995.
- Ji, Yuelong, Ramkripa Raghavan, Neha S. Anand, Guoying Wang, Xiumei Hong, Romuladus E. Azuine, Colleen Pearson, et al. 2020. “Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure with Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood.” *JAMA Psychiatry* 77 (2): 180–89.

- Kristensen, David M., Bernard Jégou, and Niels E. Skakkebæk. 2016. “Analgesic Use—Prevalence, Biomonitoring and Endocrine and Reproductive Effects.” *Nature Reviews Endocrinology* 12 (7): 381–93.
- Leppert, Beate, Daniel Strunz, Esther Walton, Jean Golding, David Llewellyn, Caroline Relton, and George Davey Smith. 2019. “Association of Maternal Neurodevelopmental Risk Alleles with Early-Life Exposures.” *JAMA Psychiatry* 76 (8): 834–42.
- Liew, Zeyan, Beate Ritz, Cristina Rebordosa, Pei-Chen Lee, and Jørn Olsen. 2014. “Acetaminophen Use During Pregnancy, Behavioral Problems, and Hyperkinetic Disorders.” *JAMA Pediatrics* 168 (4): 313–20.
- Liew, Zeyan, Beate Ritz, Jørn Olsen, and Katrine Strandberg-Larsen. 2016. “Maternal Use of Acetaminophen During Pregnancy and Risk of Autism Spectrum Disorders in Childhood: A Danish National Birth Cohort Study.” *Autism Research* 9 (9): 951–58.
- Liew, Zeyan, Andreas Ernst, Yongfu Yu, Jørn Olsen, Katrine Strandberg-Larsen, and Carsten Obel. 2021. “Prenatal Exposure to Acetaminophen and Children’s Language Development at 30 Months.” *European Psychiatry* 64 (1): e18.
- Masarwa, Reem, Ilan Levine, Einat Gorelik, Shimon Reif, Amichai Perlman, and Ilan Matok. 2018. “Prenatal Exposure to Acetaminophen and Risk for Attention Deficit Hyperactivity Disorder and Autistic Spectrum Disorder: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Cohort Studies.” *American Journal of Epidemiology* 187 (8): 1817–27.
- Navarro, Ann, Michael A. Prada, Sarah M. Evans, Lisa G. Bero, Nancy Nachman, Juleen Lam, Lauren Zeise, et al. 2025. “Evaluation of the Evidence on Acetaminophen Use and Neurodevelopmental Disorders Using the Navigation Guide Methodology.” *Environmental Health* 24 (1): 5.
- Parker, William, John F. Hornik, Susan Bilbo, Zacharoula Konidari, Lara Hernandez, Lauren Ru, et al. 2020. “The Role of Oxidative Stress, Inflammation and Acetaminophen Exposure from Birth to Early Childhood in the Induction of Autism.” *Journal of International Medical Research* 45 (2): 407–38.
- Pérez, Alexandra, Jessica R. Pochon, Sabrina L. Huebner, and Lyanne C. Schlichter. 2012. “Acetaminophen Induces Oligodendrocyte Precursor Cell Death and Reactive Astroglia in a Primary Mixed Glial Cell Culture.” *FASEB Journal* 26: 1014.
- Philippot, Gaëtan, Susanne Hallgren, Thibault Gordh, Robert Fredriksson, and Henrik Viberg. 2022. “Paracetamol (Acetaminophen) and Its Effect on the Developing Mouse Brain.” *Frontiers in Toxicology* 4: 867748.
- Posadas, Inmaculada, Pablo Santos, Alejandro Blanco-Suárez, María Moro, and Valentín Ceña. 2019. “Acetaminophen Induces Apoptosis in Rat Cortical Neurons.” *PLoS One* 5 (12): e15360.

- Riffel, Ana Paula Knorr, Marta Chagas da Silva Santos, Thales Preissler de Souza, Luana Barreto Scheid, Giovana Duzzo Gamaro, and Izabel Cristina Custódio de Souza. 2020. “Behavioral and Oxidative Parameters in Animals Exposed Prenatally to Acetaminophen.” *Environmental Toxicology and Pharmacology* 78: 103408.
- Schultz, Stephen T., Georgianna G. Gould, Helen S. Klonoff-Cohen, Janet K. Akshoomoff, and Christopher J. Newschaffer. 2008. “Acetaminophen (Paracetamol) Use, Measles-Mumps-Rubella Vaccination, and Autistic Disorder: The Results of a Parent Survey.” *Autism* 12 (3): 293–307.
- Shaw, William. 2013. “Evidence That Increased Acetaminophen Use in Genetically Vulnerable Children Appears to Be a Major Cause of the Epidemics of Autism, Attention Deficit with Hyperactivity, and Asthma.” *Journal of Restorative Medicine* 2 (1): 14–29.
- Stergiakouli, Evie, Anita Thapar, and George Davey Smith. 2016. “Association of Acetaminophen Use During Pregnancy with Behavioral Problems in Childhood: Evidence Against Confounding.” *JAMA Pediatrics* 170 (10): 964–70.
- Thompson, John M. D., Karen E. Waldie, Clare R. Wall, Rinki Murphy, Edwin A. Mitchell, and the ABC Study Group. 2014. “Associations Between Acetaminophen Use During Pregnancy and ADHD Symptoms Measured at Ages 7 and 11 Years.” *PLoS One* 9 (9): e108210.
- Torres, Anthony R. 2003. “Is Fever Suppression Involved in the Etiology of Autism and Neurodevelopmental Disorders?” *BMC Pediatrics* 3: 9.
- Viberg, Henrik, Per Eriksson, Thibault Gordh, and Anders Fredriksson. 2014. “Paracetamol (Acetaminophen) Administration During Neonatal Brain Development Affects Cognitive Function and Alters Its Analgesic and Anxiolytic Response in Adult Male Mice.” *Toxicological Sciences* 138 (1): 139–47.
- Vlenterie, Richelle, Marleen M. H. J. van Gelder, Hedwig van Hove, Mascha M. de Jong-van den Berg, and Nel Roeleveld. 2016. “Neurodevelopmental Problems at 18 Months Among Children Exposed to Paracetamol In Utero: A Propensity Score Matched Cohort Study.” *International Journal of Epidemiology* 45 (6): 1998–2008.
- Ystrom, Eivind, Kristin Gustavson, Ragnhild Eek Brandlistuen, Gun Peggy Knudsen, Per Magnus, Ezra Susser, George Davey Smith, et al. 2017. “Prenatal Exposure to Acetaminophen and Risk of ADHD.” *Pediatrics* 140 (5): e20163840.
- Zhu, Yujie, Xiaojing Wang, Bin Wang, Yongle Li, and Dezhen Wang. 2021. “Epigenetic Modifications Associated with Prenatal Acetaminophen Exposure: Systematic Review of Animal and Human Studies.” *Neurotoxicology and Teratology* 88: 107031.